The Canadian Cardiovascular Society/Canadian Heart Failure Society’s Heart Failure Guidelines are among the first to recommend that SGLT2 inhibitors be prescribed in patients with HFrEF (LVEF < 40%) and without concomitant DM, to improve symptoms and quality of life and to reduce the risk of hospitalisation and cardiovascular mortality [20]. The gene discussed is SLC5A2; the disease is diabetes mellitus.